Dramatic response of aneurysmal bone cyst to denosumab: Case report and literature review

Abstract

Abstract Denosumab, a monoclonal antibody that specifically targets cytokine receptor activator of nuclear factor‐kappa B ligand (RANKL), is a potentially viable option in resistant aneurysmal bone cysts.

Keywords

• aneurysmal bone cyst
• denosumab
• management
• RANK ligand
• resistant